Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361360 | 0.86 | PARP1 (0.51) | CYP1A2PARP1PTGER4PTGER2PARP10 | |
| SCHEMBL5363995 | 0.83 | PTGER4 (0.66) | CYP1A2PTGER4PTGER2ROCK2SMN1; SMN2 | |
| SCHEMBL4446808 | 0.82 | PTGER4 (0.59) | PTGER4PTGER2MRGPRX4EPAS1POLB | |
| SCHEMBL21359328 | 0.82 | HSD17B10 (0.48) | CYP1A2PTGER4PTGER2MRGPRX4EPAS1 | |
| SCHEMBL27933686 | 0.80 | PARP1 (0.50) | CYP1A2PARP1PARP10TNKSPARP15 | |
| SCHEMBL5362570 | 0.79 | PARP1 (0.53) | CYP1A2PARP1PTGER4PTGER2PARP10 | |
| SCHEMBL30974608 | 0.78 | ALDH1A1 (0.46) | CYP1A2KMT2AEPAS1POLBSMN1; SMN2 | |
| SCHEMBL29250429 | 0.78 | ALDH1A1 (0.46) | CYP1A2KMT2AEPAS1POLBSMN1; SMN2 | |
| SCHEMBL8901334 | 0.78 | MAPT (0.48) | PARP10PARP15PARP14KMT2AUSP2 | |
| SCHEMBL27666500 | 0.78 | PTGER4 (0.79) | PTGER4PTGER2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663979-B1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2013-10-09 | — | — | EP | disclosed |
| CN-1867551-B | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | RAQUALIA PHARMA INC | 2013-09-11 | — | — | CN | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| CN-1867551-A | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | PFIZER (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-1663979-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | CYP1A2 102/4885PARP1 3037/4885PTGER4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.